Skip to main content

Table 1 Characteristics of included patients

From: A prospective assessment of the inter-laboratory variability of biochemical markers of fibrosis (FibroTest) and activity (ActiTest) in patients with chronic liver disease

Characteristics  
Number of patients 24
Liver Disease  
   HCV 19 (79%)
   HCV-HIV 2 (8%)
   Alcohol 3 (13%)
Duration of liver disease (years) – mean (sd) 21 (4)
Age at biopsy (years) – mean (sd) 49 (11)
Age at serum sample (years) – mean (sd) 52 (11)
Duration between biopsy and serum sample (years) – mean (sd) 2.7 (1.4)
Male (%) 16 (67%)
Female (%) 8 (33%)
Mode of HCV infection  
   Transfusion (%) 6 (29%)
   IV drug use 9 (42%)
   Unknown 6 (29%)
HCV Genotype  
   3 1 (5%)
   1 20 (95%)
Baseline viral load (median in million IU/ml) 5
Fibrosis stage (unknown in 2)  
   No fibrosis (F0) 1 (5%)
   Portal fibrosis or (F1) 8 (36%)
   Few septa (F2) 7 (32%)
   Many septa (F3) 0 (0%)
   Cirrhosis (F4) 6 (27%)
Activity grade (unknown in 2)  
   None (A0) 2 (10%)
   Mild (A1) 15 (67%)
   Moderate (A2) 5 (23%)
   Severe (A3) 0 (0%)
Biopsy size (median in mm) 17
Status of patients (response to treatment)  
   Sustained responder 4 (19%)
   Relapser 1 (5%)
   Non responder 10 (48%)
   Not treated 6 (28%)
  1. HCV – hepatitis C virus; HIV – human immunodeficiency virus; sd – standard deviation.